The optimal duration of immune checkpoint inhibitors in non-oncogene addicted non-small cell lung cancer: less is more? An open question.

MLA

Giuliani, Jacopo, et al. “The Optimal Duration of Immune Checkpoint Inhibitors in Non-Oncogene Addicted Non-Small Cell Lung Cancer: Less Is More? An Open Question.” Recenti Progressi in Medicina, vol. 112, no. 12, Dec. 2021, pp. 802–04. EBSCOhost, https://doi.org/10.1701/3710.37003.

APA

Giuliani, J., Navarro, U., Mantoan, B., & Bonetti, A. (2021). The optimal duration of immune checkpoint inhibitors in non-oncogene addicted non-small cell lung cancer: less is more? An open question. Recenti Progressi in Medicina, 112(12), 802–804. https://doi.org/10.1701/3710.37003

Chicago

Giuliani, Jacopo, Ugo Navarro, Beatrice Mantoan, and Andrea Bonetti. 2021. “The Optimal Duration of Immune Checkpoint Inhibitors in Non-Oncogene Addicted Non-Small Cell Lung Cancer: Less Is More? An Open Question.” Recenti Progressi in Medicina 112 (12): 802–4. doi:10.1701/3710.37003.